Lapatinib Pharos

Lapatinib, the active ingredient in Lapatinib Pharos, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It targets HER2‑positive metastatic breast cancer and advanced gastric cancer in adult patients, inhibiting tumor cell growth.

GNH USA supplies Lapatinib Pharos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across global markets. The product is manufactured under EU GMP standards and distributed through GNH USA's global network.

Lapatinib is used to treat cancers driven by HER2 signaling. - HER2‑positive metastatic breast cancer: improves progression‑free survival when combined with chemotherapy. - HER2‑positive advanced gastric cancer: used in combination regimens to delay disease progression.

Lapatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: frequent loose stools, may lead to dehydration. - Rash: skin eruptions, often on trunk or extremities. - Nausea: mild to moderate feeling of sickness. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Cardiac dysfunction: reduced left ventricular ejection fraction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Interstitial lung disease: breathing difficulties and cough. - Hepatotoxicity: clinically significant liver injury.

When prescribing Lapatinib, clinicians should consider several precautionary measures to ensure patient safety. - Cardiac monitoring: assess baseline and periodic left ventricular function. - Liver function: evaluate hepatic enzymes before and during therapy. - Drug interactions: review concomitant medications that affect CYP3A4. - Pregnancy: avoid use unless benefits outweigh risks; discuss contraception. - Dermatologic assessment: monitor for severe skin reactions. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Lapatinib interacts with several agents that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase toxicity. - Antacids containing aluminum/magnesium: decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Paclitaxel: may increase risk of neutropenia. - Capecitabine: combined use may enhance gastrointestinal toxicity. - Warfarin: monitor INR as lapatinib may affect anticoagulation.